Blog
About

5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants.

      Journal of Acquired Immune Deficiency Syndromes (1999)

      Anti-HIV Agents, therapeutic use, adverse effects, Reverse Transcriptase Inhibitors, virology, drug therapy, Pregnancy Complications, Infectious, Pregnancy, prevention & control, Infectious Disease Transmission, Vertical, Infant, Newborn, Humans, HIV Infections, Female, Drug Therapy, Combination

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Worldwide, more than 1600 infants become infected with HIV each day. Almost all infections are a result of mother-to-child transmission of HIV, with most of these infections occurring in resource-poor countries. In developed countries, antiretroviral prophylaxis has dramatically reduced perinatal transmission to <2%. The potential now exists to extend this success to resource-poor countries using effective but shorter and less expensive antiretroviral regimens. With the potential widespread use of antiretroviral therapy for perinatal HIV prevention in resource-limited settings, there will be exposure of increasing numbers of infants to in utero and postpartum antiretroviral drugs for which long-term toxicity data is unknown. This article focuses on a review of what is known about safety of antiretroviral regimens used to interrupt mother-to-child transmission for women and their children.

          Related collections

          Author and article information

          Journal
          12045684

          Comments

          Comment on this article